TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07454603: A Single-arm, Multicenter Prospective Study to Evaluate the Diagnostic Performance of PROSTest in Men With PSA ≥ 3ng/ml Using Biopsy as the Sole Ground Truth

Sponsor: Wren Laboratories LLC · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 1500 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07454603 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07454603 Rescue Dossier →